1. Home
  2. BFRG vs IMRN Comparison

BFRG vs IMRN Comparison

Compare BFRG & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bullfrog AI Holdings Inc.

BFRG

Bullfrog AI Holdings Inc.

HOLD

Current Price

$0.66

Market Cap

6.9M

Sector

Technology

ML Signal

HOLD

Logo Immuron Limited

IMRN

Immuron Limited

HOLD

Current Price

$0.85

Market Cap

7.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BFRG
IMRN
Founded
2017
1994
Country
United States
Australia
Employees
17
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9M
7.8M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
BFRG
IMRN
Price
$0.66
$0.85
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.2M
29.1K
Earning Date
05-12-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.43
$0.68
52 Week High
$2.04
$2.38

Technical Indicators

Market Signals
Indicator
BFRG
IMRN
Relative Strength Index (RSI) 39.94 51.69
Support Level $0.65 $0.69
Resistance Level $0.69 $0.89
Average True Range (ATR) 0.05 0.07
MACD -0.03 -0.01
Stochastic Oscillator 0.46 36.89

Price Performance

Historical Comparison
BFRG
IMRN

About BFRG Bullfrog AI Holdings Inc.

Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data.

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

Share on Social Networks: